{
    "clinical_study": {
        "@rank": "41716", 
        "arm_group": [
            {
                "arm_group_label": "Oxybutynin", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Botulinum Toxin A injection", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the use of Botulinum Toxin A as primary therapy\n      for children with neurogenic bladder due to spina bifida and compare results with standard\n      oral oxybutynin therapy. This study hopes to demonstrate that Botulinum Toxin A can maintain\n      or improve bladder storage function without side effects associated with oxybutynin use."
        }, 
        "brief_title": "Botox Versus Oxybutynin as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder", 
        "completion_date": {
            "#text": "April 2012", 
            "@type": "Actual"
        }, 
        "condition": "Neurogenic Bladder", 
        "condition_browse": {
            "mesh_term": "Urinary Bladder, Neurogenic"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of spina bifida and neurogenic bladder\n\n          -  Performing clean intermittent catheterization (CIC)\n\n          -  Taking 0.3-0.4 mg/kg/day of oxybutynin for a poorly compliant bladder\n\n          -  Has not had previous bladder surgery\n\n          -  Has had a urodynamic or videourodynamic study done within the last 6 months\n\n          -  Upper motor neuron (UMN) type bladder demonstrated on last urodynamic study\n\n          -  Urodynamic study (UDS) showing either detrusor leak point pressure >40cm   H2O; 30cm\n             below capacity <60% of total bladder capacity, 20 cm     capacity <70% of bladder\n             capacity\n\n          -  Able and willing to complete CIC Diaries and Quality of Life Questionnaires\n\n          -  Consent and assent given to participate in trial\n\n        Exclusion Criteria:\n\n          -  History of lung disease, recurrent aspiration or severe neurological impairment which\n             may increase risk of Botox toxicity or anesthesia\n\n          -  Positive urine culture\n\n          -  Known allergy to Botox"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "20 Years", 
            "minimum_age": "5 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 29, 2011", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01716624", 
            "org_study_id": "R-11-140", 
            "secondary_id": "17787"
        }, 
        "intervention": [
            {
                "arm_group_label": "Oxybutynin", 
                "description": "standard oral therapy", 
                "intervention_name": "Oxybutynin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Botulinum Toxin A injection", 
                "description": "10 units/kg injected into the detrusor muscle using cystoscopy", 
                "intervention_name": "Botulinum Toxin A injection", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Oxybutynin", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Pediatric", 
        "lastchanged_date": "October 25, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "N6A 5W9"
                }, 
                "name": "London Health Sciences Centre - Victoria Hospital"
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Pilot Study Comparing the Effects of Botulinum Toxin A and Standard Oxybutynin Therapy as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder", 
        "overall_official": {
            "affiliation": "London Health Sciences Centre, Laweson Health Research Institute", 
            "last_name": "Sumit Dave, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Canada: Ethics Review Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The following urodynamic parameters will be measured;\nChange in end fill pressure or detrusor leak point pressure (cm H2O)\nChange in 20 and 30 cm H2O below volumes expressed as percentage of bladder capacity\nChange in reflex volume (percentage of bladder capacity at which neurogenic detrusor overactivity starts)", 
            "measure": "To assess urodynamic effects of intravesical botulinum toxin A injection to standard oral dose therapy", 
            "safety_issue": "No", 
            "time_frame": "Primary outcomes will be assessed at 3 and 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01716624"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Lawson Health Research Institute", 
            "investigator_full_name": "Sumit Dave", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Calculate accrual rate", 
                "safety_issue": "No", 
                "time_frame": "Secondary outcomes will be assessed at 6 months"
            }, 
            {
                "measure": "Calculate cross over rate", 
                "safety_issue": "No", 
                "time_frame": "Secondary outcomes will be assessed at 6 months"
            }, 
            {
                "measure": "Calculate adverse event rates", 
                "safety_issue": "No", 
                "time_frame": "Secondary outcomes will be assessed at 6 months"
            }, 
            {
                "measure": "Compare the side effects of standard oral therapy compared to Botulinum toxin A injection", 
                "safety_issue": "No", 
                "time_frame": "Secondary outcomes will be assessed at 6 months"
            }, 
            {
                "measure": "Calculate drop out rate", 
                "safety_issue": "No", 
                "time_frame": "Secondary outcomes will be assessed at 6 months"
            }
        ], 
        "source": "Lawson Health Research Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lawson Health Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}